Document is current
Any future updates will be listed below
-
Authors
Unger, Joseph M.
Griffin, Katherine
Donaldson, Gary W.
Baranowski, Karen M.
Good, Margorie J.
Reburiano, Eunicia
Hussain, Maha
Monk, Paul J.
Van Veldhuizen, Peter J.
Carducci, Michael A.
Higano, Celestia S.
Lara, Primo N.
Tangen, Catherine M.
Quinn, David I.
Wade, James L.
III,
Vogelzang, Nicholas J.
Thompson, Ian M.
Jr,
Moinpour, Carol M.
-
Funding
Funding for this research was provided by:
National Cancer Institute (U10CA180888, U10CA180819, UG1CA189974, U10CA37429, U10CA32102, U10CA38926)
- License Information
-
More Information
Article History
Received: 17 October 2017
Accepted: 21 May 2018
First Online: 13 June 2018
Ethics approval and consent to participate
: The study protocol was approved by Institutional Review Boards at the participating institutions enrolling cancer patients on the trial. All patients who participated in the trial and who could complete PRO forms signed detailed consent forms for the PRO component of the trial.
: CMM received support from Abbott to fund the quality of life component for S0421 but no competing interests within the last 36 months. In the last 36 months, CSH has had a spouse in leadership role for CTI Biopharma. Under Other, CSH reports serving on Advisory Boards for Aptevo, Asana, Astellas, Bayer, Blue Earth Diagnostics, Churchill, Clovis, Dendreon, Endocyte, Ferring, Medivation, MorphoSys, Orion, and Pfizer. CSH has received sponsored research from Aptevo, Bayer, Aragon, AstraZeneca, Dendreon, Exelixis, Genentech, Medivation, Millenium, Sanofi, Teva, and Pfizer. During the last 36 months, DIQ reported grant funding from Sanofi and personal fees from Sanofi, Bayer, Astellas, Dendreon, and AstraZeneca. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
